Between months four and five, most researchers are at 1.7 mg (escalated at week 13) or approaching the full 2.4 mg dose
Several barriers must be overcome when developing orally administered peptides with a molecular weight above 1,000 Da, including enzymatic degradation in the GI tract, pH-induced conformational changes, limited permeability of the intestinal membrane, and variable GI tract absorption rates [2, 3, 42, 43]
Due to insufficient fluid and nutrient uptake, this inadequacy may be further intensified
Patients with a history of pancreatitis, gallstones, or hypertriglyceridemia face elevated baseline risk
It provides a clear explanation of what your medication is for, and shows that it is medically necessary and prescribed to you